Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab.
Anti-tumor necrosis factor-a (anti-TNF-a) therapy strategies result in significant clinical benefits in patients with rheumatoid arthritis, but with an increased rate of serious infectious diseases. We describe a patient receiving infliximab who developed a primary cutaneous Nocardia otitidiscaviarum infection after a skin injury.
Fabre
Sylvie
S
Department of Immuno-Rheumatology, Centre Hospitalier Universitaire Lapeyronie, Montpellier, France.
Gibert
Christelle
C
Lechiche
Catherine
C
Jorgensen
Christian
C
Sany
Jacques
J
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D006801:Humans; D000069285:Infliximab; D008297:Male; D009617:Nocardia Infections / Q000139:chemically induced* / Q000473:pathology; D012867:Skin / Q000293:injuries; D017192:Skin Diseases, Bacterial / Q000139:chemically induced* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014947:Wounds and Injuries / Q000382:microbiology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab